{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:21:18Z","timestamp":1792120878957,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03406-1","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T08:27:24Z","timestamp":1764750444000},"page":"898-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing the Use of Inhaled Corticosteroid\/Long-Acting \u03b22-Agonist Combinations in Patients with Moderate-to-Severe Asthma"],"prefix":"10.1007","volume":"43","author":[{"given":"Gabriel","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipong","family":"Maneechotesuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhuram","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"10","key":"3406_CR1","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1007\/s12325-023-02590-2","volume":"40","author":"D Singh","year":"2023","unstructured":"Singh D, Oosterholt S, Pavord I, Garcia G, Abhijith P, Della Pasqua O. Understanding the clinical implications of individual patient characteristics and treatment choice on the risk of exacerbation in asthma patients with moderate-severe symptoms. Adv Ther. 2023;40(10):4606\u201325.","journal-title":"Adv Ther"},{"issue":"8","key":"3406_CR2","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1007\/s12325-024-02900-2","volume":"41","author":"B Aggarwal","year":"2024","unstructured":"Aggarwal B, Al-Moamary M, Allehebi R, Alzaabi A, Al-Ahmad M, Amin M, et al. APPaRENT 3: Asthma Patients' and Physicians' Perspectives on the Burden and Management of Asthma in Seven Countries. Adv Ther. 2024;41(8):3089\u2013118.","journal-title":"Adv Ther"},{"issue":"11","key":"3406_CR3","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1111\/bcp.15801","volume":"89","author":"S Oosterholt","year":"2023","unstructured":"Oosterholt S, Pavord ID, Brusselle G, Yorganc\u0131o\u011flu A, Pitrez PM, Pg A, et al. Modelling ASthma TrEatment Responses (MASTER): effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: A time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol. 2023;89(11):3273\u201390.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3406_CR4","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1007\/s12325-024-02962-2","volume":"41","author":"P Paggiaro","year":"2024","unstructured":"Paggiaro P, Garcia G, Roche N, Verma M, Plank M, Oosterholt S, et al. Baseline characteristics and maintenance therapy choice on symptom control, reliever use, exacerbation risk in moderate-severe asthma: a clinical modelling and simulation study. Adv Ther. 2024;41(11):4065\u201388.","journal-title":"Adv Ther"},{"key":"3406_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106524","volume":"186","author":"KR Chapman","year":"2021","unstructured":"Chapman KR, An L, Bosnic-Anticevich S, Campomanes CM, Espinosa J, Jain P, et al. Asthma patients\u2019 and physicians\u2019 perspectives on the burden and management of asthma. Respir Med. 2021;186:106524.","journal-title":"Respir Med"},{"key":"3406_CR6","unstructured":"2025 GINA strategy report - Global initiative for asthma - GINA 2025. Available from: https:\/\/ginasthma.org\/2025-gina-strategy-report\/."},{"issue":"4","key":"3406_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2023.100277","volume":"5","author":"V Plaza Moral","year":"2023","unstructured":"Plaza Moral V, Alobid I, \u00c1lvarez Rodr\u00edguez C, Blanco Aparicio M, Ferreira J, Garc\u00eda G, et al. GEMA 5.3. Spanish guideline on the management of asthma. Open Respiratory Archives. 2023;5(4):100277.","journal-title":"Open Respiratory Archives"},{"key":"3406_CR8","unstructured":"Asthma pathway (BTS, NICE, SIGN) 2024. Accessed 19 March 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ng244\/resources\/asthma-pathway-bts-nice-sign-pdf-66143956599493."},{"issue":"1","key":"3406_CR9","first-page":"1","volume":"40","author":"T Kawamatawong","year":"2022","unstructured":"Kawamatawong T, Sangasapaviriya A, Saiphoklang N, Oer-Areemitr N, Sriprasart T, Kamalaporn H, et al. Guidelines for the management of asthma in adults: evidence and recommendations. Asian Pac J Allergy Immunol. 2022;40(1):1\u201321.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"3406_CR10","volume":"81","author":"C Raherison-Semjen","year":"2022","unstructured":"Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, et al. Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version. Respir Med Res. 2022;81:100898.","journal-title":"Respir Med Res"},{"key":"3406_CR11","unstructured":"Asthma Workgroup; Chinese Thoracic Society; Chinese Societ of General Practitioners. Chinese guideline for the prevention and management of bronchial asthma (Primary Health Care Version). J Thorac Dis. 2013;5(5):667\u201377."},{"issue":"Suppl 1","key":"3406_CR12","doi-asserted-by":"publisher","first-page":"s11","DOI":"10.29262\/ram.v64i0.272","volume":"64","author":"D Larenas-Linnemann","year":"2017","unstructured":"Larenas-Linnemann D, Salas-Hern\u00e1ndez J, V\u00e1zquez-Garc\u00eda JC, Ortiz-Aldana I, Fern\u00e1ndez-Vega M, Del R\u00edo-Navarro BE, et al. Mexican Asthma Guidelines: GUIMA 2017. Rev Alerg Mex. 2017;64(Suppl 1):s11\u2013128.","journal-title":"Rev Alerg Mex"},{"issue":"6","key":"3406_CR13","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20210273","volume":"47","author":"RM Carvalho-Pinto","year":"2021","unstructured":"Carvalho-Pinto RM, Can\u00e7ado JED, Pizzichini MMM, Fiterman J, Rubin AS, Cerci Neto A, et al. 2021 Brazilian Thoracic Association recommendations for the management of severe asthma. J Bras Pneumol. 2021;47(6):e20210273.","journal-title":"J Bras Pneumol"},{"issue":"20","key":"3406_CR14","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","volume":"378","author":"ED Bateman","year":"2018","unstructured":"Bateman ED, Reddel HK, O\u2019Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877\u201387.","journal-title":"N Engl J Med"},{"issue":"21","key":"3406_CR15","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020\u201330.","journal-title":"N Engl J Med"},{"issue":"10202","key":"3406_CR16","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","volume":"394","author":"J Hardy","year":"2019","unstructured":"Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919\u201328.","journal-title":"Lancet"},{"issue":"20","key":"3406_CR17","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","volume":"378","author":"PM O'Byrne","year":"2018","unstructured":"O\u2019Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865\u201376.","journal-title":"N Engl J Med"},{"key":"3406_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106942","volume":"202","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Spanevello A, de Llano LP, Domingo Ribas C, Blakey JD, Garcia G, et al. Is asthma control more than just an absence of symptoms? An expert consensus statement. Respir Med. 2022;202:106942.","journal-title":"Respir Med"},{"key":"3406_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106948","volume":"201","author":"KR Chapman","year":"2022","unstructured":"Chapman KR, Canonica GW, Lavoie KL, Nenasheva N, Garcia G, Bosnic-Anticevich S, et al. Patients\u2019 and physicians\u2019 perspectives on the burden and management of asthma: results from the APPaRENT 2 study. Respir Med. 2022;201:106948.","journal-title":"Respir Med"},{"issue":"4","key":"3406_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper EF, O\u2019Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902\u20137.","journal-title":"Eur Respir J"},{"issue":"1","key":"3406_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Nathan","year":"2004","unstructured":"Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: A survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"3406_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/PPA.S234651","volume":"14","author":"S Amin","year":"2020","unstructured":"Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Understanding patient perspectives on medication adherence in asthma: a targeted review of qualitative studies. Patient Prefer Adherence. 2020;14:541\u201351.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3406_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-017-0016-z","volume":"27","author":"H Chrystyn","year":"2017","unstructured":"Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"3","key":"3406_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/1479972316687209","volume":"14","author":"WH Ramadan","year":"2017","unstructured":"Ramadan WH, Sarkis AT. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: an observational comparative study. Chron Respir Dis. 2017;14(3):309\u201320.","journal-title":"Chron Respir Dis"},{"issue":"2","key":"3406_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"key":"3406_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106670","volume":"191","author":"A Czira","year":"2022","unstructured":"Czira A, Turner M, Martin A, Hinds D, Birch H, Gardiner F, et al. A systematic literature review of burden of illness in adults with uncontrolled moderate\/severe asthma. Respir Med. 2022;191:106670.","journal-title":"Respir Med"},{"issue":"2","key":"3406_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1440-1843.2011.02105.x","volume":"17","author":"FW Ko","year":"2012","unstructured":"Ko FW, Hui DS, Leung TF, Chu HY, Wong GW, Tung AH, et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology. 2012;17(2):370\u20138.","journal-title":"Respirology"},{"issue":"4","key":"3406_CR28","first-page":"175","volume":"14","author":"M Stephen","year":"2024","unstructured":"Stephen M. The impact of asthma on lung function indices: clinical implications and management strategies. Pulm & Respir Med. 2024;14(4):175\u201391.","journal-title":"Pulm & Respir Med"},{"issue":"1","key":"3406_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/thx.47.1.14","volume":"47","author":"CS Ulrik","year":"1992","unstructured":"Ulrik CS, Backer V, Dirksen A. A 10 year follow up of 180 adults with bronchial asthma: factors important for the decline in lung function. Thorax. 1992;47(1):14.","journal-title":"Thorax"},{"issue":"6","key":"3406_CR30","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/all.16538","volume":"80","author":"CL Tsao","year":"2025","unstructured":"Tsao CL, Chan SY, Lee MH, Hsieh TYJ, Phipatanakul W, Ruran HB, et al. Adverse outcomes associated with short-acting beta-agonist overuse in asthma: a systematic review and meta-analysis. Allergy. 2025;80(6):1629\u201346.","journal-title":"Allergy"},{"issue":"5","key":"3406_CR31","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaci.2011.12.974","volume":"129","author":"KE Wells","year":"2012","unstructured":"Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason-Comstock J, Williams LK. The relationship between combination inhaled corticosteroid and long-acting \u03b2-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol. 2012;129(5):1274-9.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3406_CR32","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.rmed.2005.08.001","volume":"100","author":"KL Lavoie","year":"2006","unstructured":"Lavoie KL, Bacon SL, Labrecque M, Cartier A, Ditto B. Higher BMI is associated with worse asthma control and quality of life but not asthma severity. Respir Med. 2006;100(4):648\u201357.","journal-title":"Respir Med"},{"issue":"1","key":"3406_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-002316","volume":"11","author":"TM Kole","year":"2024","unstructured":"Kole TM, Muiser S, Kraft M, Siddiqui S, Fabbri LM, Rabe KF, et al. Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study. BMJ Open Respir Res. 2024;11(1):e002316.","journal-title":"BMJ Open Respir Res"},{"issue":"5","key":"3406_CR34","doi-asserted-by":"publisher","first-page":"1083-9","DOI":"10.1016\/j.jaci.2009.02.034","volume":"123","author":"ID Pavord","year":"2009","unstructured":"Pavord ID, Jeffery PK, Qiu Y, Zhu J, Parker D, Carlsheimer A, et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide\/formoterol. J Allergy Clin Immunol. 2009;123(5):1083-9-9 e1-7.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"3406_CR35","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s12325-023-02585-z","volume":"40","author":"P Daley-Yates","year":"2023","unstructured":"Daley-Yates P, Singh D, Igea JM, Macchia L, Verma M, Berend N, et al. Assessing the effects of changing patterns of inhaled corticosteroid dosing and adherence with fluticasone furoate and budesonide on asthma management. Adv Ther. 2023;40(9):4042\u201359.","journal-title":"Adv Ther"},{"issue":"3","key":"3406_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0615","volume":"5","author":"R Beasley","year":"2022","unstructured":"Beasley R, Harrison T, Peterson S, Gustafson P, Hamblin A, Bengtsson T, et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(3):e220615.","journal-title":"JAMA Netw Open"},{"key":"3406_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107377","volume":"218","author":"A Yorganc\u0131o\u011flu","year":"2023","unstructured":"Yorganc\u0131o\u011flu A, Cruz AA, Garcia G, Lavoie KL, Roche N, et al. A network meta-analysis of the association between patient traits and response to regular dosing with ICS\/long-acting \u03b2(2)-agonist plus short-acting \u03b2(2) agonist reliever or maintenance and reliever therapy for asthma. Respir Med. 2023;218:107377.","journal-title":"Respir Med"},{"issue":"2","key":"3406_CR38","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2023.0020","volume":"7","author":"P Pfeffer","year":"2023","unstructured":"Pfeffer P, Hajmohammadi H, Cole J, Griffiths C, Hull S, De Simoni A. Characteristics of patients with asthma overprescribed short-acting beta-agonist (SABA) reliever inhalers stratified by blood eosinophil count in North East London: a cross-sectional observational study. BJGP Open. 2023;7(2):BJGPO.2023.0020.","journal-title":"BJGP Open"},{"issue":"96","key":"3406_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1183\/09059180.05.00009606","volume":"14","author":"P Anderson","year":"2005","unstructured":"Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14(96):109\u201316.","journal-title":"Eur Respir Rev"},{"issue":"6","key":"3406_CR40","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1164\/rccm.200906-0907OC","volume":"181","author":"SR Wilson","year":"2010","unstructured":"Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med. 2010;181(6):566\u201377.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"3406_CR41","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1016\/j.jaip.2021.04.024","volume":"9","author":"OS Usmani","year":"2021","unstructured":"Usmani OS, Hickey AJ, Guranlioglu D, Rawson K, Stjepanovic N, Siddiqui S, et al. The impact of inhaler device regimen in patients with asthma or COPD. J Allergy Clin Immunol Pract. 2021;9(8):3033-40.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3406_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12890-017-0492-5","volume":"17","author":"KR Chapman","year":"2017","unstructured":"Chapman KR, Hinds D, Piazza P, Raherison C, Gibbs M, Greulich T, et al. Physician perspectives on the burden and management of asthma in six countries: the global asthma physician survey (GAPS). BMC Pulm Med. 2017;17(1):153.","journal-title":"BMC Pulm Med"},{"issue":"8","key":"3406_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0011-393X(02)80055-8","volume":"63","author":"AH Morice","year":"2002","unstructured":"Morice AH, Adler LM, Ellis S, Hewitt A. Do patients prefer dry powder inhalers or metered-dose inhalers? A retrospective, combined analysis. Curr Ther Res. 2002;63(8):496\u2013506.","journal-title":"Curr Ther Res"},{"issue":"1","key":"3406_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12931-024-03084-7","volume":"26","author":"HS Park","year":"2025","unstructured":"Park HS, Lee J, Kim H, Woo SD. Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS\/LABA combinations in asthma management. Respir Res. 2025;26(1):12.","journal-title":"Respir Res"},{"issue":"7","key":"3406_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100662","volume":"15","author":"J L\u00f3pez-Tiro","year":"2022","unstructured":"L\u00f3pez-Tiro J, Contreras-Contreras A, Rodr\u00edguez-Arellano ME, Costa-Urrutia P. Economic burden of severe asthma treatment: a real-life study. World Allergy Organ J. 2022;15(7):100662.","journal-title":"World Allergy Organ J"},{"key":"3406_CR46","unstructured":"BTS\/NICE\/SIGN. Asthma (update): Cost-utility analysis: Step-up therapy for management of uncontrolled asthma2024. Accessed June 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ng245\/documents\/economic-report-2."},{"issue":"1","key":"3406_CR47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/thoraxjnl-2019-213744","volume":"75","author":"C Janson","year":"2020","unstructured":"Janson C, Henderson R, L\u00f6fdahl M, Hedberg M, Sharma R, Wilkinson AJK. Carbon footprint impact of the choice of inhalers for asthma and COPD. Thorax. 2020;75(1):82\u20134.","journal-title":"Thorax"},{"issue":"1","key":"3406_CR48","doi-asserted-by":"publisher","first-page":"2301705","DOI":"10.1183\/13993003.01705-2023","volume":"64","author":"L Hatter","year":"2024","unstructured":"Hatter L, Holliday M, Eathorne A, Bruce P, Pavord ID, Reddel HK, et al. The carbon footprint of as-needed budesonide\/formoterol in mild asthma: a post hoc analysis. Eur Respir J. 2024;64(1):2301705.","journal-title":"Eur Respir J"},{"issue":"3","key":"3406_CR49","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1089\/jamp.2024.0060","volume":"38","author":"OS Usmani","year":"2025","unstructured":"Usmani OS, Al-Ahmad M, Allan K, Anzueto A, Braido F, Canonica GW, et al. Letter: respiratory effectiveness group position statement: inhaler choice: balancing personalized health care and environmental responsibility. J Aerosol Med Pulm Drug Deliv. 2025;38(3):145\u20137.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"1","key":"3406_CR50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/jamp.2024.0023","volume":"38","author":"N Roche","year":"2025","unstructured":"Roche N, Usmani O, Franzini L, Labadini L, Mathews KS, Panigone S, et al. Pharmaceutical, clinical, and regulatory challenges of reformulating pressurized metered-dose inhalers to reduce their environmental impact. J Aerosol Med Pulm Drug Deliv. 2025;38(1):26\u201336.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"2","key":"3406_CR51","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2022.2.2673","volume":"20","author":"RI Nassar","year":"2022","unstructured":"Nassar RI, Saini B, Obeidat NM, Basheti IA. Development and validation of the adherence to Asthma Medication Questionnaire (AAMQ). Pharm Pract (Granada). 2022;20(2):2673.","journal-title":"Pharm Pract (Granada)"},{"key":"3406_CR52","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.2147\/PPA.S358046","volume":"16","author":"S Bentley","year":"2022","unstructured":"Bentley S, Morgan L, Exall E, Arbuckle R, Rossom RC, Roche N, et al. Qualitative interviews to support development and cognitive debriefing of the Adelphi Adherence Questionnaire (ADAQ\u00a9): a patient-reported measure of medication adherence developed for use in a range of diseases, treatment modalities, and countries. Patient Prefer Adherence. 2022;16:2579\u201392.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"3406_CR53","doi-asserted-by":"publisher","first-page":"AB133","DOI":"10.1016\/j.jaci.2012.12.1144","volume":"131","author":"S Yang","year":"2013","unstructured":"Yang S, Tsoukleris MG, Lewis-Land C, Walker J, Bollinger ME, Butz A. Association between medication adherence report scale (MARS-5) and asthma outcomes in inner city children with asthma. J Allergy Clin Immunol. 2013;131(2):AB133.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03406-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03406-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:02:42Z","timestamp":1771268562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03406-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3406"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03406-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Trademarks are the property of their respective owners (QualityMetric incorporated, Asthma Control Test [ACT]; Qoltech, 5 item Asthma Control Questionnaire [ACQ-5]). Gabriel Garcia has participated in advisory boards for GSK, AstraZeneca, Sanofi, Novartis and Boehringer-Ingelheim; he has received honoraria for speaking at sponsored meetings from GSK, Boehringer-Ingelheim, AstraZeneca, Sanofi, Phoenix and Novartis, and is a principal investigator in trials sponsored by GSK, Boehringer-Ingelheim, AstraZeneca, Novartis, Sanofi, PPD, Zambon, Parexel, Covance, IQVIA and Chiesi. Nicolas Roche is in receipt of grants from Chiesi, GSK, Pfizer; personal consulting fees from AstraZeneca, Austral, Biosency, Chiesi, GSK, Pfizer, Roche, Sanofi; personal payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Chiesi, GSK, Menarini, MSD, Sanofi, Zambon; and support for attending meetings and\/or travel from AstraZeneca, Chiesi, and GSK. Kittipong Maneechotesuwan has received honoraria for lectures, presentations, speakers\u2019 bureaus or educational events from AstraZeneca, Boehringer Ingelheim, GSK, Novartis and Sanofi. Prabhuram Krishnan and Manish Verma are employees of and hold financial equities in GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}